Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

I
EP-029
IDENTIFICATION OF A SAFE AND TOLERABLE CARBAMAZEPINE DOSING PARADIGM THAT FACILITATES EFFECTIVE CYP3A INDUCTION EVALUATION.

Favorite
PI-019
IDENTIFICATION OF S100A9 AS A THERAPEUTIC TARGET IN PACLITAXEL-INDUCED PERIPHERIAL NEUROPATHY (PIPN).

Favorite
PII-030
IMPACT OF COMORBID PAIN, PSYCHIATRIC DIAGNOSES, AND SUBSTANCE USE DISORDERS ON OPIOID USE DISORDER TREATMENT IN PERSONS WITH AND WITHOUT HIV.

Favorite
RWE-003
IMPACT OF COMORBID PAIN, PSYCHIATRIC DIAGNOSES, AND SUBSTANCE USE DISORDERS ON OPIOID USE DISORDER TREATMENT IN PERSONS WITH AND WITHOUT HIV.

Favorite
LB-009
IMPACT OF INTRAMUSCULAR INJECTION SITE ON SOTROVIMAB PHARMACOKINETICS.

Favorite
PWIV-004
IMPACT OF PREGNANCY ON THE PHARMACOKINETICS AND METABOLISM OF NICOTINAMIDE IN HUMANS.

Favorite
PI-088
IMPACT OF PREGNANCY ON THE PHARMACOKINETICS AND METABOLISM OF NICOTINAMIDE IN HUMANS.

Favorite
PI-020
IMPACT OF TYROSINE KINASE INHIBITOR (TKI) DOSAGE MODIFICATIONS ON PROGRESSION-FREE SURVIVAL (PFS) IN THE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC).

Favorite
PI-072
IN VITRO AND IN VIVO POTENTIAL OF ZURANOLONE TO CAUSE CYP-MEDIATED DRUG-DRUG INTERACTIONS.

Favorite
PII-013
IN VITRO, IN SILICO, AND CLINICAL INVESTIGATIONS OF BLU-5937 AS PERPETRATOR OF DRUG-DRUG INTERACTIONS.

Favorite
PII-104
INDIVIDUAL DOSE OPTIMIZATION FOR SOMATROGON BY MODELING AND SHINY INTERFACE.

Favorite
EP-025
INDUCED PLURIPOTENT STEM CELLS (IPSCS) AS A MODEL TO STUDY THIOPURINE INDUCED PANCREATITIS: PERSONALIZATION OF THERAPY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

Favorite
PII-047
INFLAMMATION DRIVEN INHIBITION OF CYP2C19 METABOLISM OF VORICONAZOLE IN THE TREATMENT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.

Favorite
PT-008
INFLUENCE OF MCT6 ON PLATINUM DISPOSITION AND OTOTOXICITY.

Favorite
PII-003
INTEGRATED CELLULAR KINETIC (CK) – PHARMACODYNAMIC (PD) ANALYSIS FOR FIRST IN HUMAN DOSE-ESCALATION STUDY OF TAK-102: A GPC3 TARGETED AUTOLOGOUS CAR-T CELLS ARMORED WITH IL-7 AND CCL19.

Favorite
EP-002
INTEGRATED METABOLOMICS ANALYSIS REVEALS MECHANISTIC INSIGHTS INTO THE ANCESTRAL DIFFERENCES IN PLASMA RENIN ACTIVITY AMONG PATIENTS WITH HYPERTENSION AND THIAZIDE DIURETICS BLOOD PRESSURE LOWERING EFFECTS.

Favorite
PI-073
INTEGRATED MODEL-BASED ANALYSIS UTILIZING CO-EXPRESSED CHECKPOINT INHIBITOR DATA TO INFORM THE RECOMMENDED DOSE FOR EXPANSION (RDE) OF ANTI-TIGIT MAB M6223.

Favorite
PII-048
INTERETHNIC DIFFRENCE IN (S)-WARAIN PHARMACOKINETICS AND EXTENT OF ANTICOAGULATION BETWEEN ETHIOPIAN AND NON-ETHIOPIAN JEWS.

Favorite
PI-099
INTERNATIONAL COMPARISON OF THE NUMBER OF PHASE 3 CLINICAL TRIALS FOR COVID-19.

Favorite
PII-055
INVESTIGATING THE EFFECT OF INFORMATIVE CENSORING ON THE KAPLAN-MEIER ESTIMATE OF ENDPOINTS IN ONCOLOGY CLINICAL TRIALS.

Favorite
PII-034
INVESTIGATION OF DRUG COMBINATIONS IN CANCER THROUGH UNBIASED IDENTIFICATION OF RECURRING DRUG RESPONSE PATTERNS IN CELL LINES.

Favorite
PII-105
INVESTIGATION OF THE BIOTRANSFORMATION OF TRIHEXYPHENIDYL AND APPLICATION TO DYSTONIC CEREBRAL PALSY.

Favorite